These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27995532)

  • 1. Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan.
    Kubota S; Saito K; Ono S; Kodama Y
    Drugs R D; 2017 Mar; 17(1):133-143. PubMed ID: 27995532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan.
    Tamaki C; Nagayama T; Hashiba M; Fujiyoshi M; Hizue M; Kodaira H; Nishida M; Suzuki K; Takashima Y; Ogino Y; Yasugi D; Yoneta Y; Hisada S; Ohkura T; Nakamura K
    J Toxicol Sci; 2013; 38(4):581-98. PubMed ID: 23824014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.
    Nakayama H; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2019 Feb; 33(1):45-52. PubMed ID: 31933266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management.
    Dambach DM; Simpson NE; Jones TW; Brennan RJ; Pazdur R; Palmby TR
    Clin Cancer Res; 2016 Jun; 22(11):2618-22. PubMed ID: 27250932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Drug Reactions for Medicines Newly Approved in Japan from 1999 to 2013: Hypertension and Hypotension.
    Nagayama T; Nishida M; Hizue M; Ogino Y; Fujiyoshi M
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):306-12. PubMed ID: 26407539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in Japan.
    Uzu S; Sato J; Wakao R; Nonaka T
    BMC Health Serv Res; 2022 Oct; 22(1):1292. PubMed ID: 36289504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Safety Profiles of Blood Cancer Drugs Approved in Japan.
    Kubota S; Saito K; Ono S; Kodama Y
    Ther Innov Regul Sci; 2016 Mar; 50(2):228-235. PubMed ID: 30227012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translation of nonclinical to clinical safety findings for 27 biotherapeutics.
    Leach MW; Rana P; Hu W; Mittapalli RK; Pinkstaff J; Potter D; Qiu XM; Ramaiah L; Rohde C; Xia F; Khan KN
    Toxicol Appl Pharmacol; 2024 Mar; 484():116854. PubMed ID: 38346540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety analysis of therapeutic drugs for breast cancer patients and construction of a predictive model for serious adverse drug reactions.
    Lin S; Lei S; Liu W; Zhu X; Ren B; Feng B
    Eur J Clin Pharmacol; 2024 Feb; 80(2):249-259. PubMed ID: 38099939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
    Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
    J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan.
    Ishiguro A; Yagi S; Uyama Y
    J Hum Genet; 2013 Jun; 58(6):313-6. PubMed ID: 23657427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan.
    Uhara H; Kiyohara Y; Tsuda A; Takata M; Yamazaki N
    Clin Transl Oncol; 2018 Feb; 20(2):169-175. PubMed ID: 28674996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection.
    Tuccori M; Montagnani S; Capogrosso-Sansone A; Mantarro S; Antonioli L; Fornai M; Blandizzi C
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):61-75. PubMed ID: 25363790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability.
    Lavan AH; O'Mahony D; Buckley M; O'Mahony D; Gallagher P
    Oncologist; 2019 Sep; 24(9):e968-e977. PubMed ID: 30833488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
    Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
    J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.